Cip/Kip proteins: more than just CDKs inhibitors: Figure 1.
2004; Cold Spring Harbor Laboratory Press; Volume: 18; Issue: 8 Linguagem: Inglês
10.1101/gad.1205304
ISSN1549-5477
AutoresCatherine Denicourt, Steven F. Dowdy,
Tópico(s)Ubiquitin and proteasome pathways
ResumoMembers of the Cip/Kip family of cyclin-dependent kinases inhibitors (CKIs) are well characterized for their role as negative regulators of G 1 -phase cell-cycle progression (Sherr and Roberts 1999).In eukaryotic cells, progression through the cell cycle is governed by a suite of cyclins and cyclin-dependent kinase (CDKs) complexes (Murray 2004).Regulation of cyclin-CDKs complexes occurs at multiple levels, including assembly of cyclin and CDK subunits, inhibitory and activating phosphorylation and dephosphorylation events, and association of cyclin-CDK complexes with CKIs.During these regulatory processes, cyclin-CDK complexes positively drive progression of the cell cycle, whereas by binding to and inactivating cyclin-CDKs, CKIs negatively regulate progression through the cell cycle.Based on their sequence homology and specificity of action, CKIs are divided into two distinct families: INK4 and Cip/Kip (Sherr and Roberts 1999).Members of the INK4 family, namely p15, p16, p18, and p19 specifically inhibit the activity of CDK4 and CDK6, whereas Cip/Kip members, that is, p21, p27, and p57 inhibit a broader spectrum of cyclin-CDK complexes (el-Deiry et al.
Referência(s)